Sun Pharmaceutical Industries Ltd. received a warning letter from the US health regulator for its Dadra facility over a violation of manufacturing norms.
The warning letter by the US Food and Drug Administration summarises violations with respect to current good manufacturing practice regulations, the company said in an exchange filing on Wednesday.
The contents of the warning letter issued by the US health regulator shall be made public in due course, it added.
This intimation is further to our communication dated Apr. 11, 2024, about the Dadra facility receiving OAI status from the USFDA.
On Apr. 11, Sun Pharma informed stock exchanges that its Dadra facility had received official action-indicated status from the USFDA.
It followed an inspection at the company's Dadra facility from December 4 to Dec. 15, 2023.
(With Inputs From PTI)
RECOMMENDED FOR YOU
Democrats Share Trump-Signed Epstein Birthday Letter Once Denied By President
Sep 09, 2025
Experts Warn India's Future At Risk As Young Lungs Deteriorating, Struggle To Breathe
Sep 08, 2025
Lupin Gets USFDA Nod For Generic Risperidone Extended-Release Injectable Suspension
Sep 03, 2025
Rains Making You Spend More? Breaking Down Seasonal Expenses From Transport To Medicines
Aug 20, 2025
POPULAR